Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NRSN Stock Forecast 2026-2027
$0.88
Current Price
$31.77M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NRSN Price Targets
+1,490.9%
To High Target of $14.00
+837.5%
To Median Target of $8.25
+240.9%
To Low Target of $3.00
NRSN Price Momentum
-1.1%
1 Week Change
+25.7%
1 Month Change
-15.4%
1 Year Change
+14.3%
Year-to-Date Change
-66.2%
From 52W High of $2.60
+39.7%
From 52W Low of $0.63
📊 TOP ANALYST CALLS
Did NRSN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if NeuroSense is one of their latest high-conviction picks.
Latest NRSN Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, NRSN has a bullish consensus with a median price target of $8.25 (ranging from $3.00 to $14.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.88, the median forecast implies a 837.5% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 1,490.9% upside. Conversely, the most conservative target is provided by Boobalan Pachaiyappan at Roth Capital, suggesting a 240.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NRSN Analyst Ratings
4
Buy
0
Hold
0
Sell
NRSN Price Target Range
Low
$3.00
Average
$8.25
High
$14.00
Current: $0.88
Latest NRSN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NRSN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $14.00 |
| Mar 25, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $14.00 |
| Mar 17, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $14.00 |
| Mar 10, 2026 | Roth Capital | Boobalan Pachaiyappan | Buy | Initiates | $3.00 |
| Mar 9, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $14.00 |
| Dec 22, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $14.00 |
| Nov 24, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $14.00 |
| Aug 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $14.00 |
| Jul 10, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $14.00 |
| May 12, 2025 | D. Boral Capital | Jason Kolbert | Buy | Initiates | $14.00 |
| Dec 16, 2024 | Maxim Group | Naz Rahman | Hold | Downgrade | $N/A |
| Jul 17, 2023 | Alliance Global Partners | James Molloy | Buy | Initiates | $7.50 |
| Jan 7, 2022 | Maxim Group | Naz Rahman | Buy | Initiates | $7.00 |
Neurosense Therapeutics Ltd. (NRSN) Competitors
The following stocks are similar to NeuroSense based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Neurosense Therapeutics Ltd. (NRSN) Financial Data
Neurosense Therapeutics Ltd. has a market capitalization of $31.77M with a P/E ratio of -2.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -2,175.0%.
Valuation Metrics
Market Cap
$31.77M
Enterprise Value
$31.11M
P/E Ratio
-2.0x
PEG Ratio
-1.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.6%
Current Ratio
0.3x
Debt/Equity
-0.1x
ROE
-2,175.0%
ROA
-247.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Neurosense Therapeutics Ltd. (NRSN) Business Model
About Neurosense Therapeutics Ltd.
What They Do
Develops treatments for neurodegenerative diseases.
Business Model
Neurosense Therapeutics operates as a clinical-stage biotechnology company, focusing on the research and development of innovative drug compounds for neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's. The company generates value by advancing its drug candidates through rigorous clinical trials and collaborating with academic institutions to validate its scientific approaches.
Additional Information
By addressing unmet medical needs with its novel therapeutic solutions, Neurosense positions itself as a significant player in the biotechnology sector, aiming to improve the quality of life for millions of patients affected by debilitating disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
17
CEO
Mr. Alon Ben-Noon
Country
Israel
IPO Year
2021
Website
www.neurosense-tx.comNeurosense Therapeutics Ltd. (NRSN) Latest News & Analysis
Latest News
Quick Summary
NeuroSense Therapeutics secured financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, with participation from a major existing shareholder.
Why It Matters
Leadership involvement in financing signals confidence in NeuroSense's future, potentially boosting investor sentiment and stock performance. Existing shareholder support highlights trust in the company's prospects.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
NeuroSense Therapeutics has secured patent protection until October 2042, enhancing its global intellectual property portfolio following prior grants in the U.S. and Australia.
Why It Matters
NeuroSense's extended patent protection enhances its competitive edge and revenue potential, signaling strong future profitability and security for investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
NeuroSense Therapeutics has until September 29, 2026, to regain compliance with Nasdaq requirements. The company is working on initiatives to support long-term shareholder value.
Why It Matters
The notification indicates regulatory scrutiny, which could signal financial instability. Compliance efforts may impact future performance and shareholder value, influencing stock sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
1 month ago
Quick Summary
NeuroSense Therapeutics' PrimeC has entered late-stage clinical trials for ALS, showing a 65% reduced risk of death and over 14 months median survival advantage. Results published in JAMA Neurology.
Why It Matters
NeuroSense's positive Phase 3 ALS results and FDA clearance enhance its valuation and market potential, signaling strong investor confidence and possible future profitability.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
NeuroSense Therapeutics Ltd. announced news from Cambridge, Mass. on March 24, 2026. Further details were not provided in the excerpt.
Why It Matters
NeuroSense Therapeutics' announcement may signal developments in biotech, impacting stock value and market sentiment, particularly in the neuroscience sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
NeuroSense Therapeutics is set to present advancements in its PrimeC treatment for ALS, focusing on Phase 2 clinical results and biomarker insights, ahead of a Phase 3 trial.
Why It Matters
NeuroSense's progress in ALS treatment could impact stock value and investor sentiment, indicating potential for breakthrough therapies and future revenue growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NRSN Stock
What is Neurosense Therapeutics Ltd.'s (NRSN) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Neurosense Therapeutics Ltd. (NRSN) has a median price target of $8.25. The highest price target is $14.00 and the lowest is $3.00.
Is NRSN stock a good investment in 2026?
According to current analyst ratings, NRSN has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.88. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NRSN stock?
Wall Street analysts predict NRSN stock could reach $8.25 in the next 12 months. This represents a 837.5% increase from the current price of $0.88. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neurosense Therapeutics Ltd.'s business model?
Neurosense Therapeutics operates as a clinical-stage biotechnology company, focusing on the research and development of innovative drug compounds for neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's. The company generates value by advancing its drug candidates through rigorous clinical trials and collaborating with academic institutions to validate its scientific approaches.
What is the highest forecasted price for NRSN Neurosense Therapeutics Ltd.?
The highest price target for NRSN is $14.00 from Jason Kolbert at D. Boral Capital, which represents a 1,490.9% increase from the current price of $0.88.
What is the lowest forecasted price for NRSN Neurosense Therapeutics Ltd.?
The lowest price target for NRSN is $3.00 from Boobalan Pachaiyappan at Roth Capital, which represents a 240.9% increase from the current price of $0.88.
What is the overall NRSN consensus from analysts for Neurosense Therapeutics Ltd.?
The overall analyst consensus for NRSN is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.25.
How accurate are NRSN stock price projections?
Stock price projections, including those for Neurosense Therapeutics Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 1:24 AM UTC